PSY
Psychedelic ETF
PSY
Mental illnesses are on the rise and existing medications have been found wanting. A staggering 30% of depression patients do not respond to any currently available treatment.1 Research budgets for psychiatric medicine in large companies have fallen dramatically over the last decade, as confidence wanes that more investment in the same direction will produce improved results.2
Recent breakthrough studies in the medical repurposing of psychedelics and ketamine have found significant benefits to sufferers of anxiety, PTSD, OCD, eating disorders, depression and others. Declared a “breakthrough therapy,” by the FDA in 2018 and 2019, studies on the use of psilocybin have found rapid, marked, and enduring anti-anxiety and depression effects.
Invest in the Future of Psychedelics and Medical Cannabis
PSY is the first US-listed psychedelic ETF. It seeks to track the BITA Medical Psychedelics, Cannabis, and Ketamine Index, a rules-based index that tracks the performance of a portfolio of companies listed on North American Exchanges conducting legal activities under the national laws of the applicable country related to medical psychedelics, medical cannabis, cannabis pharmaceuticals and cannabidiol (“CBD”) derivatives, and ketamine.
Companies included in the index must have a minimum market capitalization of $75 million, and operate in the production, distribution, or services related to medical psychedelics, medical cannabis or other medicinal drugs and their derivatives.
—
1 “Compass Pathways (NASDAQ:CMPS) IPO Proves Psychedelic Medicine Investment Thesis, WPSS Investments Newswire,” October 1, 2020. https://www.globenewswire.com/news-release/2020/10/02/2102708/0/en/compass-pathways-nasdaq-cmps-ipo-proves-psyche%c2%acdelic-medicine-investment-thesis.html
2 “Big pharma pulling back from mental health drug research: studies,” October 29, 2012, https://www.ctvnews.ca/health/health-headlines/big-pharma-pulling-back-from-mental-health-drug-research-studies-1.1015154
Fund Data and Pricing
Fund Details
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | -7.86% | -20.21% | xx.xx% | xx.xx% | -17.13% |
| Market Price (%) | xx.xx% | -7.10% | -19.83% | xx.xx% | xx.xx% | -16.63% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | -7.80% | xx.xx% | xx.xx% | xx.xx% | -10.06% |
| Market Price (%) | xx.xx% | -7.93% | xx.xx% | xx.xx% | xx.xx% | -10.26% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | -6.07% | xx.xx% | xx.xx% | xx.xx% | -2.45% |
| Market Price (%) | xx.xx% | -6.27% | xx.xx% | xx.xx% | xx.xx% | -2.53% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% | xx.xx% | xx.xx% | xx.xx% | 3.86% |
| Market Price (%) | xx.xx% | xx.xx% | xx.xx% | xx.xx% | xx.xx% | 4.00% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| Name | Symbol | Stock price | % Price change | % Net assets | Shares Held | Market Value | |
|---|---|---|---|---|---|---|---|
 | Cardiol Therapeutics Inc-a | CRDL CN | $5.40 | 0.00% | 5.52% | 126,400 | 535,152 |
 | Compass Pathways Plc | CMPS | $32.10 | -5.34% | 5.32% | 15,560 | 515,658 |
| Forian Inc | FORA | $20.00 | -11.13% | 5.29% | 44,580 | 512,670 | |
| Gh Research Plc | GHRS | $0.00 | -6.48% | 5.13% | 23,500 | 496,790 | |
 | Atai Life Sciences Nv | ATAI | $15.82 | -4.69% | 5.11% | 30,160 | 495,227 |
 | Zynerba Pharmaceuticals Inc | ZYNE | $4.26 | -1.42% | 5.07% | 116,000 | 490,680 |
 | Seelos Therapeutics Inc | SEEL | $1.92 | -4.00% | 4.96% | 240,100 | 480,200 |
 | Pharmacielo Ltd | PCLO CN | $1.23 | 0.00% | 4.91% | 493,160 | 475,587 |
 | Cronos Group Inc | CRON CN | $7.59 | 0.00% | 4.88% | 79,460 | 472,854 |
 | Neptune Wellness Solutions Inc Com | NEPT | $0.58 | -10.77% | 4.85% | 722,560 | 469,664 |
| Download Fund Documents |
|---|
 |
 |
 |
 |
 |
 |
 |
 |
Distribution
| Ex-Date | Total Distribution |
|---|---|
| 09/22/2021 | xx |
Download Distribution Schedule  | |
Reasons to Invest
Psychedelic future
Imagine if a non-addictive, short term intervention with minimal side effects could dramatically improve mental health? Psychedelics could be a part of such treatment.
Next Gen. Medicine
Psychedelics promote neural plasticity, essentially allowing the brain to rewire itself. Recipients report unparalleled insight and paradigm shifts akin to mystical or spiritual awakenings.
Growth Potential
Psilocybin, LSD and their derivatives could become an integral part of the multi-billion dollar global medicine market; offering hope to many whose conditions seem untreatable in current paradigms.
Marijuana
PSY also offers exposure to companies leading the medical repurposing of cannabis, to treat chronic pain, symptoms of MS, and side effects of chemotherapy among others.
